Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Surgical Blood Management Using Noninvasive and Continuous Hemoglobin Monitoring(NACHO)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2013 by Tel-Aviv Sourasky Medical Center
Sponsor:
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01753960
First received: November 5, 2012
Last updated: January 1, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to determine whether Noninvasive and Continuous Hemoglobin Monitoring (NACHO) for Surgical Blood Management affects transfusion decision making algorithm in the operating room.


Condition
Hemorrhage

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management (NACHO) - Matched-pair Cluster-randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Number of allogeneic Red Blood Cells (RBC) units transfused intraoperatively [ Time Frame: perioperative period untill the end of surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Hospital stay treatment - Occurrence of any allogeneic RBC transfusions intraoperatively [ Time Frame: From end of surgery until 30 days after surgery ] [ Designated as safety issue: No ]
  • Hospital stay treatment - Total number of allogeneic RBC units transfused perioperatively during hospital stay [ Time Frame: From end of surgery until 30 days after surgery ] [ Designated as safety issue: No ]
  • Hospital stay treatment - Incidence of new (or worsening of pre-existing) ischemic events [ Time Frame: From end of surgery until 30 days after surgery ] [ Designated as safety issue: No ]
  • Hospital stay treatment - 30-day mortality [ Time Frame: From end of surgery until 30 days after surgery ] [ Designated as safety issue: No ]
  • Hospital stay treatment - Length of post-surgery hospital stay [ Time Frame: From end of surgery until 30 days after surgery ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: January 2013
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control group
Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
SpHb group
Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.

Detailed Description:

Blood transfusions are associated with various risks including viral infections, delayed wound healing, transfusion related acute lung injury and cardiovascular complications. Despite limitations, and ongoing efforts to identify and validate other more-physiologically-relevant "triggers" for blood transfusions, hemoglobin-based transfusion triggers are still commonly used in practice, as well as in all currently available transfusion guidelines, alone, or in combination with other parameters. In the operating room the anesthesiologist has to withdraw blood from the patient and send it to the lab or the blood gas machine to achieve hemoglobin levels. It may be suggested that the ability to continuously monitor hemoglobin levels may help physicians to take more appropriate transfusion decisions; i.e, the physicians will either identify critical decreases in hemoglobin levels earlier and respond appropriately or avoid over-transfusing when hemoglobin levels have not decreased yet. Accordingly, monitors of hemoglobin levels are used in the operating theatre in many centers, although their blood-conserving effect has not been proven yet.

We believe that the transfusion decision making algorithm in the operating room relies less heavily on "on spot" measures of hemoglobin levels but rather on patient's comorbidities, expected additional bleeding according to the surgery and the surgeon, the course of the operation (the operating field is "open" and thus surgeons can tell if it is oozing or frank bleeding, if they can control bleeding promptly or not etc..), hemodynamic data available from the different invasive and non-invasive monitors, pressure from the surgeon, etc. It is therefore suggested that continuous monitoring of hemoglobin levels may be less relevant in this environment.

Specific Aims/Hypothesis:

  1. The primary hypothesis is that continuous noninvasive hemoglobin monitoring will not reduce the number of blood transfusions in patients undergoing surgeries associated with a significant risk of bleeding.
  2. The secondary hypothesis is that in patients monitored with continuous noninvasive hemoglobin, there will not be earlier warning of critical drops in hemoglobin, resulting in less frequent complications compared with patients who are not being monitored with continuous noninvasive hemoglobin.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Study population in this study is defined at two levels: 1.Consenting eligible Anesthesiologists, and 2. Eligible patients under the case of the consenting eligible Anesthesiologist. Each level has its own eligibility criteria.

Criteria
  1. Anesthesiologists Eligibility Criteria

    Inclusion Criteria:

    • Consenting anesthesiologist
    • Anticipate to manage at least 10 cases per month
    • At least 3-year post-graduate clinical experience as an anesthesiologist responsible for making transfusion decisions for individual patients

    Exclusion Criteria:

    • Not meeting the appropriate licensing requirements
    • No being board-certified in Anesthesiology
    • Inability or unwillingness to complete study-related procedures, including undergoing training with regards to using and interpreting the monitor data in the operating room
  2. Eligible patients under the case of the consenting eligible Anesthesiologist.

Inclusion criteria:

150 Adult patients undergoing major surgeries associated with possibility of significant blood loss (e.g. such that blood is cross-matched and available before the start of the case as per hospital routine practice).

  • Consenting patients who are primarily managed by the consenting anesthesiologists participating in the study
  • At least one finger available and accessible for performing non-invasive hemoglobin monitoring.

Exclusion criteria:

  • Any patients who do not fit the criteria for use of sensor, specifically, any patient with nail polish and/or a nail deformity, or obstructed physical access (e.g. due to bandage) to all fingers that would be used for sensor placement, in a manner that interferes with satisfactory sensor placement
  • Any patients being monitored with motor evoked potential devices
  • Any patients with a known hemoglobinopathy
  • Any patients undergoing Cardio-Pulmonary Bypass (CPB)
  • Any patients who cannot be transfused or has refused consent for a blood transfusion
  • Patients who are moribund/salvage cases as determined by the participating anesthesiologist in charge of management of the patient in the operating room
  • Patients being treated by any artificial oxygen carriers within 30 days of hospital stay
  • Patients being managed outside of an operating room, or in operating room with conditions not conducive to perform and complete the study procedures (including use of the hemoglobin monitoring device)
  • Patients younger than 18 years old
  • Patients who are pregnant
  • Any patients expected to receive transfusion preoperatively
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01753960

Contacts
Contact: Idit Matot, Professor 97236974758 ext 4758 iditm@tasmc.health.gov.il

Locations
Israel
Tel-Aviv Sourasky Medical Center Not yet recruiting
Tel-Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Idit Matot, professor Tel-Aviv Sourasky Medical Center
  More Information

No publications provided

Responsible Party: Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT01753960     History of Changes
Other Study ID Numbers: TASMC-12-IM-0561-12-CTIL
Study First Received: November 5, 2012
Last Updated: January 1, 2013
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Hemorrhage
Pathologic Processes

ClinicalTrials.gov processed this record on November 24, 2014